Tidao, Julieta L.
HRN: 21-20-65 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/04/2022
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
05/04/2022
05/10/2022
IV
1.5g
Q6hours
CAP-MR; Presumptive TB
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes